Autoimmune Diseases: Clinical Trials

8375 completed, 2070 unknown, 1849 recruiting, 1018 terminated. 4166 Not applicable, 2694 Phase 2, 1876 Phase 3, 1743 Phase 1, 1040 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	4166	Completed 2331, Unknown 650, Recruiting 468, Not yet recruiting 226, Terminated 175, Active not recruiting 168, Withdrawn 90, Enrolling by invitation 43, Suspended 15
Phase 2	2694	Completed 1430, Recruiting 329, Terminated 322, Unknown 252, Withdrawn 121, Not yet recruiting 116, Active not recruiting 111, Enrolling by invitation 10, Suspended 3
Phase 3	1876	Completed 1147, Terminated 177, Recruiting 172, Unknown 145, Active not recruiting 118, Withdrawn 62, Not yet recruiting 44, Enrolling by invitation 10, Suspended 1
Phase 1	1743	Completed 995, Recruiting 248, Terminated 142, Unknown 122, Not yet recruiting 88, Withdrawn 70, Active not recruiting 66, Enrolling by invitation 7, Suspended 5
Phase 4	1040	Completed 592, Unknown 173, Terminated 95, Recruiting 84, Withdrawn 38, Not yet recruiting 29, Active not recruiting 24, Enrolling by invitation 5
Early Phase 1	231	Recruiting 64, Completed 59, Not yet recruiting 39, Unknown 35, Withdrawn 13, Terminated 10, Active not recruiting 4, Suspended 4, Enrolling by invitation 3

Follow Autoimmune Diseases: new trials by email Literature Review of Autoimmune Diseases trials Research Report on Autoimmune Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Comparison of Vigorous Versus Low Intensity Cool Room Treadmill Training in People with Multiple Sclerosis Body-weight supported treadmill training in a room cooled to 16°C - Multiple Sclerosis, Neurological Rehabilitation	Not applicable	Withdrawn	Memorial University of Newfoundland		2030-01-01	2024-11-27
Cannabichromene Safety in Rheumatoid Arthritis Cannabichromene - Arthritis, Rheumatoid	Phase 1 / Phase 2	Withdrawn	Crystal Lederhos Smith		2028-07-15	2026-09-23
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NM8074 - IgA Nephropathy	Phase 2	Not yet recruiting	NovelMed Therapeutics	10	2028-02-01	2026-04-13
Insul-In This Together: Leveraging Family Support and Diabetes Technology for Adolescents Living With Type 1 Diabetes Insul-In This Together - Diabetes Type 1	Not applicable	Not yet recruiting	Stanford University	200	2028-01-01	2026-10-05
An Open-label Study of GC012F in Rheumatoid Arthritis. LD and GC012F CAR-T Cell Injection, GC012F CAR-T Cell Injection - Rheumatoid Arthritis	Early Phase 1	Withdrawn	Institute of Hematology & Blood Diseases Hospital, China		2027-12-01	2026-06-10
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus	Phase 1	Withdrawn	Caribou Biosciences, Inc.		2027-12-01	2025-09-19
Blood Biomarkers for Prognostic Stratification in Guillain-Barré Syndrome Blood Biomarker Panel Assessment (EGR1, EGR2, GBP1, miR-29c, and Piccolo) - Guillain Barré Syndrome		Recruiting	Anahuac University	140	2027-12-01	2026-11-13
Inductive Therapeutic Exercise in Multiple Sclerosis Experimental: Inductive Therapeutic Exercise (ETI), Control: Sham Inductive Therapeutic Exercise (sham-ETI) - Multiple Sclerosis	Not applicable	Not yet recruiting	Fundación San Juan De Dios	30	2027-10-01	2026-10-02
Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis Acetyl Salicylic Acid (ASA), Placebo - Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS)	Phase 3	Not yet recruiting	Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal	120	2027-10-01	2026-10-30
GLP-1 RA for Stage 1 Type 1 Diabetes Semaglutide, Placebo - Stage 1 Diabetes Mellitus, Type 1	Phase 2	Not yet recruiting	Children's Hospital Medical Center, Cincinnati	15	2027-09-01	2026-02-24
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy	Early Phase 1	Not yet recruiting	Grit Biotechnology	30	2027-08-01	2026-09-11
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease MHB018A injection - Thyroid Eye Disease (TED)	Phase 3	Not yet recruiting	Minghui Pharmaceutical (Hangzhou) Ltd	219	2027-07-01	2026-06-04
Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells fetal MSCs combined with 4SCAR T cells - Autoimmune Diseases	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	30	2027-06-30	2026-11-02
Exploring Reproductive Decision-Making Among Women With Multiple Sclerosis Multiple Sclerosis		Not yet recruiting	Assiut University	272	2027-06-01	2026-09-21
CAR-T Cells Targeting Autoimmune Diseases 4SCAR T cells - Autoimmune Diseases	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	30	2027-06-01	2026-11-02
A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC - Autoimmune Encephalitis (AE)	Phase 2	Not yet recruiting	argenx	170	2027-04-01	2026-09-22
CKM For Safe Use of SGLT2i in Type 1 Diabetes Sotagliflozin Low Dose, Sotagliflozin High Dose, Dual Continuous Glucose and Ketone Monitor - Type 1 Diabetes (T1D)	Phase 3	Not yet recruiting	University of California, San Diego	52	2027-04-01	2026-11-04
Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG Myasthenia Gravis Generalized		Not yet recruiting	BioSensics	25	2027-03-15	2026-10-13
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive	Phase 2	Not yet recruiting	Moein Amin	20	2027-03-01	2026-08-19
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy C-CAR168 - Systemic Sclerosis (SSc), Systemic Sclerosis	Phase 1	Not yet recruiting	AbelZeta Inc.	12	2027-03-01	2026-10-13

Showing 20 of 15319. Sign in to see all of them.

Narrower conditions

Diabetes Mellitus, Type 1 (3573)  ·  Arthritis, Rheumatoid (3290)  ·  Multiple Sclerosis (3165)  ·  Lupus Erythematosus, Systemic (1188)  ·  Diabetes Mellitus (774)  ·  Multiple Sclerosis, Relapsing-Remitting (617)  ·  Purpura, Thrombocytopenic, Idiopathic (483)  ·  Diabetes Mellitus, Type 2 (456)  ·  Motor Activity (391)  ·  Arthritis, Juvenile (359)  ·  Lupus Nephritis (336)  ·  Sjogren's Syndrome (322)  ·  Myasthenia Gravis (320)  ·  Fatigue (287)

Broader conditions

Immune System Diseases (15186)  ·  Skin and Connective Tissue Diseases (5729)  ·  Connective Tissue Diseases (5149)  ·  Nervous System Diseases (4800)  ·  Autoimmune Diseases of the Nervous System (4348)  ·  Musculoskeletal Diseases (4163)  ·  Endocrine System Diseases (4059)  ·  Joint Diseases (3890)  ·  Rheumatic Diseases (3873)  ·  Demyelinating Diseases (3837)  ·  Nutritional and Metabolic Diseases (3832)  ·  Metabolic Diseases (3756)  ·  Demyelinating Autoimmune Diseases, CNS (3681)  ·  Arthritis (3667)

Interventions

Methotrexate (331)  ·  Rituximab (302)  ·  tocilizumab (214)  ·  Blood Specimen Collection (180)  ·  Adalimumab (174)  ·  Etanercept (170)  ·  Insulin Aspart (168)  ·  Prednisone (168)  ·  Cyclophosphamide (148)  ·  Exercise (140)  ·  Mycophenolic Acid (137)  ·  Abatacept (127)  ·  Methylprednisolone (127)  ·  Insulin (120)  ·  Insulin Glargine (116)

Sponsors

Hoffmann-La Roche (279)  ·  Novo Nordisk A/S (241)  ·  Novartis Pharmaceuticals (218)  ·  Assiut University (195)  ·  Biogen (192)  ·  Assistance Publique - Hôpitaux de Paris (163)  ·  Pfizer (150)  ·  Amgen (141)  ·  Sanofi (140)  ·  GlaxoSmithKline (135)  ·  Eli Lilly and Company (129)  ·  Bristol-Myers Squibb (125)  ·  AstraZeneca (102)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (100)  ·  University of Colorado, Denver (83)

Countries

United States (5173)  ·  France (1766)  ·  China (1505)  ·  Germany (1456)  ·  United Kingdom (1307)  ·  Canada (1220)  ·  Italy (1154)  ·  Spain (1141)  ·  Poland (911)  ·  Turkey (Türkiye) (730)  ·  Belgium (682)  ·  Czechia (605)  ·  Netherlands (585)  ·  Australia (579)  ·  Denmark (549)

Results publications

PMID 33687069, PMID 38299639, PMID 36600185, PMID 36601090, PMID 36931693, PMID 36526796, PMID 32816215, PMID 33127856, PMID 34870800, PMID 28143815, PMID 39192350, PMID 25047021, PMID 27338778, PMID 34778952, PMID 38958913, PMID 29244149, PMID 30649524, PMID 37453736, PMID 39735417, PMID 26275429, PMID 33263165, PMID 34706874, PMID 37528520, PMID 40465397, PMID 29463520, PMID 34041702, PMID 34628605, PMID 34741731, PMID 38864363, PMID 26032537, PMID 31072380, PMID 31610021, PMID 36205910, PMID 37747626, PMID 19005182, PMID 21387374, PMID 28205039, PMID 28941219, PMID 30177460, PMID 33023488, PMID 34531304, PMID 35577477, PMID 36715850, PMID 36754548, PMID 36814062, PMID 37308218, PMID 37945286, PMID 37982966, PMID 38775637, PMID 40875187

NIH funding

2023 (120), 2015 (83), 2025 (83), 2014 (78), 2018 (74), 2009 (73), 2017 (70), 2019 (66), 2016 (65), 2008 (48), 2005 (21), 2004 (13), U54AR057319 (8), R01DK085623 (7), UC4DK117009 (7)